查詢結果分析
來源資料
相關文獻
- Vaccine Development for Hepatitis C: Lessons from the Past Turn into Promise for the Future
- 慢性C型肝炎之治療
- C型肝炎
- 臺灣新竹地區C型肝炎病毒感染之血清流行病學研究
- C型病毒性肝炎治療與研究
- Detection and Treatment of Acute Hepatitis C by Needlestick Among Medical Personnel
- 醫療尖銳物品扎傷追蹤調查
- Seroepidemiology of Hepatitis C Virus Infection Among Drug Abusers in Southern Taiwan
- 綜觀C型肝炎病毒
- C型肝炎的臨床表徵
頁籤選單縮合
題 名 | Vaccine Development for Hepatitis C: Lessons from the Past Turn into Promise for the Future=C型肝炎疫苗的發展:過去的經驗變為將來的希望 |
---|---|
作 者 | 胡志棠; | 書刊名 | 慈濟醫學 |
卷 期 | 17:2 民94.04 |
頁 次 | 頁61-74+129 |
分類號 | 418.293 |
關鍵詞 | C型肝炎; 結合表位; 疫苗接種; 細胞毒殺T淋巴細胞; 幫助T淋巴細胞; Hepatitis C; Epitopes; Vaccination; Cytotoxic T lymphocytes; Helper T lymphocytes; |
語 文 | 英文(English) |
中文摘要 | 本期文章中,胡志棠醫師整理了C 型肝炎疫苗發展的最新狀況,亦指出一些具前瞻性的疫苗發展策略。劉安邦醫師等人探應以重覆DNA疫苗注射是否可誘發免疫力正常的小黑鼠,對大腸桵菌半乳酶產生新生兒免疫兔受性,同時也發現疫苗的投予方式會決定是否產生耐受性。黃呂津醫師等人進行回溯性胃腸道糞石的臨床研究,發現胃腸道糞石的患者,以男性居多,而下段迴腸是最常阻塞的位置。黃士銘醫師等人利用BUdR的特色,發現BUdR的標記指數與分化性甲狀腺癌多種臨床預後因子具有意義的關係。王宗仁醫師等人檢視過去四個內硬腦膜動靜脈瘻管併有眼科學表現之病例,以顱內硬腦膜動靜脈瘻管可能會造成眼科方面的症狀做為起始表現。徐莉萍醫萱等人探討東臺灣頭頸部鱗狀上皮細胞癌之遠隔轉移情形、及可能的危險日子,以供未來治療的參考。 第17卷第1期之基刊發行後,獲得很好的迴響。目前除了版面印刷要求精美外,內容部分亦在加強中,其待大家的努力可使本刊早日躋身國際之林。 慈濟醫學雜誌自本期起,增擘「醫學倫理」專欄,除約稿外,亦歡迎各界讀者踴躍投稿,來稿以中文為寥,約一千字,並請附上英文題目及摘要。 |
英文摘要 | Most natural hepatitis C virus (HCV) infection elicits poor immune responses and 75% to 85% of HCV infections become chronic; therefore, the development of an effective vaccine is of paramount importance. HCV was discovered in 1988 and there is still no vaccine for it. Impediments in the devlepoment of a globally effective hepatitis C vaccine include the following: (1) the lack of a susceptible small animal model; (2) tge genetic and serological heterogeneity of hepatitis C virus, especially the hypervariable region of the envelope glycoprotein E2 , which contains a principal neutralization epitope; (3) modest titers of hsort-lived neutralizing antibody response to the envelope proteins emerge too late to prevent chronic infection; (4) failure ot produce high quantities of HCV in tissue culture. Lessons form the past indicate that a lobally effective HCV vaccine should elicit high-titer, long-lasting, cross-reactive anti-envelope antibodies and induce a vigorous, multispectific cellular immune response that includes both helper and cross-reactive anti-envelope antibodies andinduce a vigorous, multispecific cellular immune response that includes both helper and cytotoxic T lymphocytes, particularly of the Th1 type. The successful vaccine may require multiple components that rarget various aspects of protective immunity, possibly in parallel when more of the various HCV epitorpes are found. A polyepitope-based strategy combing HCV lie aprticles and conserved T-cell epitopes in HCV non-structural proteins could fulfill these cristeia. This review summarizes the present status and hgihelights novel promising strategies in HCV vaccine development. |
本系統中英文摘要資訊取自各篇刊載內容。